Despite the strong evidence suggesting that PAI-1 plays a key role in obesity-related T2DM and NAFLD, no studies have described or investigated a mechanistic link between PAI-1 and dyslipidemia. Here, SERPINE1 is linked to metabolic dysfunction-associated steatotic liver disease.